SEC Comment Letter 0000000000-22-013835 to Altamira Therapeutics Ltd. (CYTO) (CIK 0001601936) (CYTOF)
Altamira Therapeutics Ltd. (CYTO) (CIK 0001601936)
Date: Dec. 22, 2022 · CIK: 0001601936 · Accession: 0000000000-22-013835
AI Filing Summary & Sentiment
File numbers found in text: 333-268838
Letter
United States securities and exchange commission logo December 22, 2022 Marcel Gremaud Chief Financial Officer Altamira Therapeutics Ltd. Clarendon House 2 Church Street Hamilton HM 11 Bermuda Re:Altamira Therapeutics Ltd. Registration Statement on Form F-1 Filed December 16, 2022 File No. 333-268838 Dear Marcel Gremaud: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Alan Campbell at 202-551-4224 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Tracy Buffer
Show Raw Text
United States securities and exchange commission logo
December 22, 2022
Marcel Gremaud
Chief Financial Officer
Altamira Therapeutics Ltd.
Clarendon House
2 Church Street
Hamilton HM 11
Bermuda
Re:Altamira Therapeutics Ltd.
Registration Statement on Form F-1
Filed December 16, 2022
File No. 333-268838
Dear Marcel Gremaud:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Alan Campbell at 202-551-4224 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc: Tracy Buffer